Cougar Biotechnology (now part of Johnson & Johnson)
 

This annual report, issued the first year Cougar went public, focused on
the Phase I clinical trial of what is now marketed as ZYTIGA (abiraterone acetate), a metastatic castration-resistant prostate cancer treatment.  

CougarBiotechnology pg 2.jpg
CougarBiotechnology2007AnnualReport.pg.
CougarBiotechnology2007AnnualReport.pg 6
CougarBiotechnology2007AnnualReport.pg 5